The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Lohberger, Birgit ^a   Stuendl, Nicole ^a   Wolf, Elisabeth ^a   Liegl Atzwanger, Bernadette ^a   Leithner, Andreas ^a   Rinner, Beate ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

ALDH1; Cancer stem cells; Myxofibrosarcoma; SNP analysis; STR profiling

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; B RAF KINASE; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; SCATTER FACTOR RECEPTOR; SMOOTHENED PROTEIN; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAF GENE; CANCER GROWTH; CANCER STEM CELL; CARCINOGENICITY; CASE REPORT; CELL LINE MUG MYX1; CELL POPULATION; CELL PROLIFERATION; CHROMOSOME 5; CHROMOSOME MAP; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME ACTIVITY; EPIGENETICS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MET GENE; MLL3 GENE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SHORT TANDEM REPEAT; SMO GENE; TIF GENE; TUMOR CELL LINE; TUMOR GENE; UPREGULATION;

AGED; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FIBROSARCOMA; GENE EXPRESSION; HUMANS; ISOENZYMES; KARYOTYPE; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; RETINAL DEHYDROGENASE; THORACIC NEOPLASMS;

EID: 84888380340     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-563     Document Type: Article

References (42)

1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. Myxofibrosarcoma. WHO Classification of Tumors of Soft Tissue and Bone 2013, 93-94. Geneva (Switzerland): World Health Organization Classification of Tumors, 4.
2. Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 2004, 35:612-621. 10.1016/j.humpath.2004.01.016, 15138937.
3. Lin CN, Chou SC, Li CF, Tsai KB, Chen WC, Hsiung CY, Yen CF, Huang HY. Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol 2004, 93:294-303.
4. Huang HY, Huang WW, Wu JM, Huang CK, Wang JW, Eng HL, Lin CN, Chou SC, Yu SC, Fang FM, Lee JC, Li CF. Flow cytometric analysis of DNA ploidy and S-phase fraction in primary localized myxofibrosarcoma: correlations with clinicopathological factors, Skp2 expression, and patient survival. Ann Surg Oncol 2008, 15:2239-2249. 10.1245/s10434-008-9968-0, 18516647.
5. Hajj MA, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:74-82.
6. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res 2006, 66:9339-9344. 10.1158/0008-5472.CAN-06-3126, 16990346.
7. Ginestier C, Hur MH, Charafe-Jauffret E, Monvile F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 15:555-567.
8. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, Gabrielson KL, Matsui W, Maitra A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007, 67:2187-2196. 10.1158/0008-5472.CAN-06-3281, 3073370, 17332349.
9. Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell 2007, 15:485-487.
10. Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl-Atzwanger B, Walzer SM, Windhager R, Leithner A. Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS One 2012, 7(8):e43664. 10.1371/journal.pone.0043664, 3426519, 22928012.
11. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55(4):611-622. 10.1373/clinchem.2008.112797, 19246619.
12. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3(7):RESEARCH0034. 126239, 12184808.
13. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer 1977, 39:1672-1685. 10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C, 192434.
14. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD. Myxofibrosarcoma. Clinicopathological analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 1996, 20:391-405.
15. Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, Casali PG, Gronchi A. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 2011, 18:720-725. 10.1245/s10434-010-1341-4, 20878245.
16. Jefford CE, Irminger-Finger I. Mechanisms of chromosome instability in cancers. Crit Rev Oncol Hematol 2006, 59:1-14. 10.1016/j.critrevonc.2006.02.005, 16600619.
17. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005, 5:773-785. 10.1038/nrc1714, 16195750.
18. Slominski A, Wortsman J, Carlson A, Mihm M, Nickoloff B, McClatchey K. Molecular pathology of soft tissue and bone tumors. A review. Arch Pathol Lab Med 1999, 23:1246-1259.
19. Conway C, Chalkley R, High A, Maclennan K, Berri S, Chengot P, Alsop M, Egan P, Morgan J, Taylor GR, Chester J, Sen M, Rabbitts P, Wood HM. Next-generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumors. J Mol Diagn 2012, 14(2):104-111. 10.1016/j.jmoldx.2011.10.003, 22240447.
20. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J, Ylstra B, Yue JP, Gray JW, Jain AN, Pinkel D, Albertson DG. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001, 29:263-264. 10.1038/ng754, 11687795.
21. Mertens F, Fletcher CD, Antonescu CR, Coindre JM, Colecchia M, Domanski HA, Downs-Kelly E, Fisher C, Goldblum JR, Guillou L, Reid R, Rosai J, Sciot R, Mandahl N, Panagopoulos I. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest 2005, 85(3):408-415. 10.1038/labinvest.3700230, 15640831.
22. Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, Wan X, Baker KS, Sorensen P, Barr FG. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer 2002, 33:310-321. 10.1002/gcc.10026, 11807989.
23. Ohguri T, Hisaoka M, Kawauchi S, Sasaki K, Aoki T, Kanemitsu S, Matsuyama A, Korogi Y, Hashimoto H. Cytogenetic analysis of myxoid liposarcoma and myxofibrosarcoma by array-based comparative genomic hybridisation. J Clin Pathol 2006, 59:978-983. 10.1136/jcp.2005.034942, 1860469, 16751306.
24. Stock C, Kager L, Fink FM, Gadner H, Ambros PF. Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 2000, 28:329-336. 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F, 10862039.
25. Tarkkanen M, Kiuru-Kuhlefelt S, Blomqvist C, Armengol G, Böhling T, Ekfors T, Virolainen M, Lindholm P, Monge O, Picci P, Knuutila S, Elomaa I. Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet Cytogenet 1999, 114:35-41. 10.1016/S0165-4608(99)00031-X, 10526533.
26. Tarkkanen M, Wiklund TA, Virolainen MJ, Larramendy ML, Mandahl N, Mertens F, Blomqvist CP, Tukiainen EJ, Miettinen MM, Elomaa AI, Knuutila YS. Comparative genomic hybridization of postirradiation sarcomas. Cancer 2001, 92:1992-1998. 10.1002/1097-0142(20011001)92:7<1992::AID-CNCR1719>3.0.CO;2-2, 11745275.
27. Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, Lin YT, Wu JM, Tsai JW, Li SH, Huang HY. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol 2010, 23(10):1379-1392. 10.1038/modpathol.2010.128, 20639860.
28. Tsai JW, Li CF, Kao YC, Wang JW, Fang FM, Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, Yu SC, Lan J, Huang HY. Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator. Ann Surg Oncol 2012, 19(8):2716-2725. 10.1245/s10434-012-2317-3, 22476749.
29. Tuna M, Ju Z, Amos CI, Mills GB. Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy. BMC Med Genomics 2012, 5:60-67. 10.1186/1755-8794-5-60, 3541987, 23217126.
30. Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 2006, 19(3):407-416. 10.1038/modpathol.3800550, 16415793.
31. Look Hong NJ, Hornicek FJ, Raskin KA, Yoon SS, Szymonifka J, Yeap B, Chen YL, DeLaney TF, Nielsen GP, Mullen JT. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol 2013, 20(1):80-86. 10.1245/s10434-012-2572-3, 22890594.
32. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111. 10.1038/35102167, 11689955.
33. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037. 10.1158/0008-5472.CAN-06-2030, 17283135.
34. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Strass SA, Katz RL. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338. 10.1158/1541-7786.MCR-08-0393, 19276181.
35. Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010, 32:1195-1201. 10.1002/hed.21315, 2991066, 20073073.
36. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R, Stassi G. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 2010, 70:8874-8885. 10.1158/0008-5472.CAN-10-1994, 20959469.
37. An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells?. Expert Opin Drug Metab Toxicol 2009, 5(12):1529-1542. 10.1517/17425250903228834, 19708828.
38. Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010, 86:631-637. 10.1016/j.lfs.2010.02.012, 20159023.
39. Murphy MJ, Wilson A, Trumpp A. More than just proliferation: Myc function in stem cells. Trends Cell Biol 2005, 15:128-137. 10.1016/j.tcb.2005.01.008, 15752976.
40. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676. 10.1016/j.cell.2006.07.024, 16904174.
41. Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat 2012, 133(1):75-81. 10.1007/s10549-011-1692-y, 21818590.
42. Hellsten R, Johansson M, Dahlman A, Sterner O, Bjartell A. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PLoS One 2011, 6(7):e22118. 10.1371/journal.pone.0022118, 3133629, 21779382.